Schematic of mechanistic mechanism by which AXL activates YAP (IMAGE)

Hiroshima University

Schematic of mechanistic mechanism by which AXL activates YAP

Caption

Scientists from Hiroshima University Hospital clarified the mechanism by which AXL heterodimerizes with EGFR to activate the EGFR-LATS1/2-YAP axis, resulting in proliferation and resistance against EGFR-targeted drugs (left). These results suggest that the combination of the drug targeting AXL or YAP with EGFR targeted therapy may be beneficial for preventing cancer recurrence and progression acquired by YAP re-activation.

Credit

Toshinori Ando, Hiroshima University Hospital

Usage Restrictions

News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.